contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dagens-aktienyheder-2006-expres2ion-og-impero

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics.

The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

ExpreS2ion Biotech Holding

Impero is a Danish Software-as-a-Service (SaaS) company that provides a compliance management platform. The Impero platform enables companies to easily manage compliance through the automation of risk and control management, documentation, and reporting. Impero empowers companies to become more compliant in a scalable, digital, intuitive, and – most importantly – easy way. Impero is listed at Nasdaq First North in Denmark.

Impero

Dagens aktienyheder med ExpreS2ion Biotechnologies og Impero

ExpreS2ion meddelte i g&#xe5;r, at selskabets associerede selskab, AdaptVac (hvor ExpreS2ion ejer 34%), er blevet udvalgt til at lede et konsortium, der har modtaget et tilskud p&#xe5; USD 12,4 millioner fra CEPI og Den Europ&#xe6;iske Unions Horizon Europe-program. Tilskuddet skal st&#xf8;tte udviklingen af en ny vaccine, der er designet til at yde samlet beskyttelse mod flere d&#xf8;delige filovirus. Udover det var der i flere aviser fokus p&#xe5; et studie, hvori Adaptvac sammen med forskere fra K&#xf8;benhavns Universitet, fors&#xf8;ger at g&#xf8;re de meget anvendte mRNA-vacciner bedre ved at skabe en mere langvarig respons -&#xa0; noget som har v&#xe6;ret et problem for netop mRNA-vacciner. L&#xe6;s mere her: <a class="x1i10hfl xjbqb8w x1ejq31n x18oe1m7 x1sy0etr xstzfhl x972fbf x10w94by x1qhh985 x14e42zd x9f619 x1ypdohk xt0psk2 xe8uvvx xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x16tdsg8 xggy1nq x1a2a7pz x1s688f x1heor9g x1bvjpef xujl8zx" tabindex="-1" role="link" href="https://www.inderes.dk/analyst-comments/expres2ion-biotechnologies-adaptvac-part-of-consortium-receiving-usd-124m-in-grants?fbclid=IwZXh0bgNhZW0CMTAAYnJpZBEwSWdPc2had0NJV3k4M3FIagEeIjkJ3TmlD4anuFn9EpPKgVu6lVD5K3myafsTncnkdih9gvC6Upvx5qP6JYY_aem_RB31GnP1SlPwaaK5ROPH0g" target="_blank" rel="nofollow noopener noreferrer">https://www.inderes.dk/analyst-comments/expres2ion-biotechnologies-adaptvac-part-of-consortium-receiving-usd-124m-in-grants</a>
Impero meddelte i g&#xe5;r, at selskabets nye bestyrelsesmedlemmer Christian Stendevad (gennem selskabet Peira ApS) og Charlotte Rosendahl Dohm (gennem selskabet LCM Invest) begge har k&#xf8;bt 71.000 aktier til en kurs p&#xe5; DKK 7,00 per aktie svarende til en v&#xe6;rdi p&#xe5; DKK 497.000 hver. De i alt 142.000 aktier er solgt af Imperos CEO Rikke Stampe Skov.&#xa0;
Disclaimer: HC Anderen Capital modtager betaling fra de n&#xe6;vnte selskaber for en digital IR/Corporate Visibility abonnementsaftale.
/Kasper Lihn d. 20/06-2025 kl. 09:09 (opdateret kl. 09:12).

Dagens aktienyheder 20/06: ExpreS2ion og Impero

Stay up to date